Advances in treatment have extended the survival of patients with multiple myeloma (MM),[1] but this increased survival time also increases the potential for developing second primary malignancies ...
No takes yet. Share an insight, caveat, or question.
Rifkin et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: